Filing Flows › Comparisons › CCCC vs BSEM
C4 Therapeutics vs BioStem Technologies: CCCC and BSEM compared
C4 Therapeutics is the larger company: $8.5M of revenue in its latest quarter (Q3 2026) against $7.9M for BioStem Technologies (Q2 2026). C4 Therapeutics is growing faster (-25% against -28% a year earlier). BioStem Technologies is more profitable, with an operating margin of -106.3% against -290.5%.
Where the money goes: CCCC and BSEM
C4 Therapeutics (CCCC) · Q3 2026
C4 Therapeutics, Q3 2026: revenue $8.5M (-25% year over year), operating margin -290.5%, net loss $21.8M, operating cash flow −$26.0M. The chart follows the revenue to costs, profit and cash.
BioStem Technologies (BSEM) · Q2 2026
BioStem Technologies, Q2 2026: revenue $7.9M (-28% year over year), operating margin -106.3%, net loss $9.0M. The chart follows the revenue to costs, profit and cash.
| C4 Therapeutics (CCCC) | BioStem Technologies (BSEM) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $8.5M | $7.9M |
| Revenue growth, Y/Y | -25% | -28% |
| Operating margin | -290.5% | -106.3% |
| Net earnings | −$21.8M | −$9.0M |
| Net margin | -257.9% | -113.6% |
| Operating cash flow | −$26.0M | — |
Where the revenue comes from
BioStem Technologies
- Hospital: $6.7M (85%)
- Physician Office: $1.1M (14%)
- Other: $89K (1%)
Questions
Which is bigger, C4 Therapeutics or BioStem Technologies?
C4 Therapeutics is the larger company: $8.5M of revenue in its latest quarter (Q3 2026) against $7.9M for BioStem Technologies (Q2 2026).
Is C4 Therapeutics or BioStem Technologies growing faster?
C4 Therapeutics is growing faster (-25% against -28% a year earlier).
Which is more profitable, C4 Therapeutics or BioStem Technologies?
BioStem Technologies is more profitable, with an operating margin of -106.3% against -290.5%.
More: C4 Therapeutics earnings · how C4 Therapeutics makes money · BioStem Technologies earnings · how BioStem Technologies makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.